Notícias

Johnson & Johnson (NYSE:JNJ) has proposed a whopping $5.5 billion settlement to resolve tens of thousands of lawsuits that allege its baby powder and ‌other talc products cause ovarian cancer. The proposed settlement could finally provide investors with the visibility they have lacked for over a decade into one of the company’s largest legal liabilities. […]

Healthcare investors looking for long-term growth don’t always have to choose between fast-growing companies and defensive businesses. Sometimes the more interesting decision is between two high-quality companies that are growing for entirely different reasons. Johnson & Johnson (NYSE:JNJ) continues to benefit from the breadth of its pharmaceutical and medical technology businesses, while Thermo Fisher’s (NYSE:TMO) […]

These two high-quality dividend payers have had very different fortunes recently.

American States Water has quietly been increasing its dividend for over 70 years.

Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.

Reaching $6,600 a month in dividend income sounds like a single-number problem, but the capital you actually need swings by more than a million dollars depending on which yield tier you choose and what you give up to get there.

Collecting over $141,000 a year in dividends without selling a single share sounds like a fantasy until you realize the yield you chase determines whether your income grows, stagnates, or quietly cannibalizes itself.

Johnson & Johnson (NYSE: JNJ) received European Commission approval for TECVAYLI®▼ (teclistamab) plus daratumumab for adults with relapsed or refractory multiple myeloma. The decision allows use of the combination as early as second line for patients whose disease has returned or is not responding to prior treatment. The approval is based on Phase 3 data that showed material improvements in patient outcomes versus existing standards of care. This adds another immunotherapy option to Johnson...

Generating $19,000 a month from dividends alone sounds like a single problem with one answer, but the yield you chase changes the required nest egg by millions and introduces a completely different set of risks, tax consequences, and long-term tradeoffs.

Starting yield and dividend growth pull $465,000 in two very different directions over a decade, and choosing the wrong one at 53 could cost you far more than the yield gap suggests.

Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.

With US procedure growth slowing and the shares well below their high, the operating margin has widened in each of the last three years.

What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S

Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.

JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.

MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ahead of Keytruda's 2028 LOE.

JNJ's diversified portfolio and pipeline strength offer an edge over MRK as both face patent expiration challenges.

In the latest trading session, Johnson & Johnson (JNJ) closed at $267.37, marking a -2.21% move from the previous day.

Johnson & Johnson (JNJ) is back in focus after its stock moved higher following a 6.6% rise in second quarter sales and an improved outlook for 2026. See our latest analysis for Johnson & Johnson. The recent second quarter update and regulatory news around Johnson & Johnson's MONARCH QUEST 3 system have come alongside strong momentum, with a 30 day share price return of 9.88% and an 81.38% total shareholder return over three years. This suggests investors have increasingly rewarded its...

The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.

The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.

Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.

You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.

The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.

AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.

Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%